|

Targeting NUDT21 siRNA drugs Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • Eye & ENT Hospital of Fudan University1

Indications

  • Refractory1
  • Retinoblastoma1
  • Cancer1

Other1 trial

Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.